RBC use is typically greatest for hip arthroplasty compared with other procedures, 2 but wide variation in RBC transfusion requirements has been described between centres and individual surgeons. 3 4 Despite the publication of clinical transfusion
guidelines, there appears to be widespread variation in beliefs regarding safe transfusion practice, including between anaesthetists. 5 As the number of patients undergoing arthroplasty increases, and larger numbers of patients live longer, the number of revision hip arthroplasty (RHA) procedures performed has increased significantly in most health-care systems. Published studies indicate that patients undergoing RHA frequently require RBC transfusions at higher rates than the other high-volume orthopaedic procedures. 2 6 There has been increased interest in perioperative blood conservation for orthopaedic surgery in recent years, and lower RBC use for surgery is increasingly considered a quality marker. 6 7 Drivers for blood conservation include the greater cost of RBCs, reduced donation rates, concerns regarding the risks of receiving allogeneic RBCs, and patient preference to avoid receiving blood transfusions. Blood conservation strategies include preoperative autologous donation, preoperative erythropoietin therapy, perioperative red cell salvage, and antifibrinolytic drugs. 6 7 Of these, sys-drugs. Systematic reviews of available evidence suggest that these technologies are effective for some patients undergoing orthopaedic surgery, but interpretation is difficult because heterogeneous procedures were included, and many studies were carried out before restrictive haemoglobin (Hb) transfusion triggers were adopted based on evidencebased guidelines. 6 9-11 The primary aim of this study was to explore the factors associated with the risk of allogeneic RBC transfusion for a single surgical procedure with a high-risk of perioperative RBC transfusion, RHA, in a representative sample of Scottish hospitals. We were particularly interested in the impact of perioperative cell salvage (PCS) on the risk of receiving RBC transfusions.
Methods
We used data from a previously published survey of blood conservation in revision hip surgery, 12 together with surgical procedure data from the Scottish Transfusion Epidemiology Database (which covers all National Health Service hospital sites in Scotland), to identify all hospitals in Scotland that undertake revision hip surgery. No minimum number of procedures was set, and some hospitals undertook ,10 procedures per year. We identified 24 hospitals using this process. We used available procedural data to group hospitals into three groups: .100 procedures per year (n¼2), 30-100 procedures per year (n¼10), and ,30 procedures per year (n¼12). We planned to collect data prospectively from half of the hospitals (n¼12). For each of the three groups, 50% of the hospitals were chosen at random as study sites. These sites were approached to participate in data collection; all sites approached agreed to collaborate. The study was reviewed by the Scottish Multicenter ethics committee, who classified it as audit/service evaluation. The need for individual patient consent was waived.
As this was a descriptive study, no formal sample size calculation was undertaken. The steering group agreed by consensus to a recruitment target of 200 cases. Assuming a transfusion rate of 50-60% of cases, we expected to obtain data for 100-120 patients in whom transfusion occurred, which would allow regression modelling for 10-12 variables assuming one variable per 10 events of interest (exposure to allogeneic RBC transfusion). Based on known case numbers in the centres, we calculated that 7 months of recruitment at eligible sites would acquire 200 cases assuming 100% data collection.
Data collection
The data fields were agreed a priori by the steering group with additional input from collaborating orthopaedic surgeons and anaesthetists.
Baseline data collection comprised relevant patient characteristics (gender, age), co-morbidities (hypertension, ischaemic heart disease, chronic obstructive pulmonary disease, cerebrovascular disease, rheumatoid arthritis, diabetes mellitus, chronic anaemia), medication (aspirin, clopidogrel, warfarin, heparin, oral iron, erythropoietin), orthopaedic history (underlying diagnosis, reason for arthroplasty revision), and preoperative Hb. Day of surgery data comprised the operation performed, anaesthetic technique (general, general plus regional, regional alone), use of perioperative cell salvage, re-infusion volume (for salvaged patients), antifibrinolytic use, RBC transfusion [in the operating theatre, total on day of surgery], and estimated blood loss. Hb data comprised all routinely measured Hb values up to day 7 after operation. RBC use data comprised RBC units transfused in the operating theatre, and all RBC transfusions up to day 7 post-surgery. The timing of all RBC transfusions was recorded and related to measured Hb values. The use of other blood products was also recorded.
Baseline data and day of surgery data were collected by anaesthetists, surgeons or both and operating theatre nursing staff. Postoperative data were collected by transfusion practitioners or other dedicated staff. All data were recorded on a case record file. Data were checked by a member of the study team and any queries resolved against source data.
Analysis
Descriptive statistics were used to document baseline patient characteristics and day of surgery data. Three RBC transfusion outcomes were calculated: first, RBC transfusions in the operating theatre; secondly, RBC transfusions from discharge from the operating theatre to 7 days after operation (or time of hospital discharge if ,7 days); thirdly, the entire perioperative period including the operating theatre to 7 days after operation. Hb data were used to describe preoperative anaemia and rates of anaemia for postoperative days 1-7. For all RBC transfusions on days 1-7, we calculated the preceding Hb value as a measure of the transfusion trigger used.
We dichotomized the cohort according to the use of PCS and described RBC use for these subgroups.
Multivariable analysis
We chose exposure to allogeneic RBCs from day 0 (day of surgery) to day 7 post-surgery as a binary outcome for logistic regression analysis. The factors included in our regression modelling are listed in Table 1 . We developed two models: first, we examined the preoperative, surgical, and anaesthetic factors associated with allogeneic RBC transfusion (excluding subsequent theatre blood loss and use of PCS). This model was intended to potentially inform decisions regarding when blood conservation technologies are likely to be most effective; secondly, we included estimated operating theatre blood loss and the use of PCS to the model to explore the relative contribution of salvage to avoidance of allogeneic RBC transfusion.
For all models, backward conditional binary logistic regression was used, excluding any variables with P.0.1. Statistical significance was taken as P≤0.05. Associations are presented as odds ratio (OR) with 95% confidence intervals (95% CI).
Results
During the study period, hospital records showed that there were 210 RHAs in the 12 hospitals. Data were available for all cases. As predicted, there was wide variation in caseload, and one site did not undertake an RHA during the study period (Table 2) . Data were therefore only evaluated from 11 hospitals.
Patient characteristics and baseline data are shown in Table 3 . The mean (95% CI
, and a higher proportion of females had a preoperative Hb concentration of ,100 g litre 21 (females 7.0% vs males 3.1%). None of the patients underwent preoperative autologous red cell donation or erythropoietin therapy as these are not routinely offered in Scotland before orthopaedic surgery. The surgery performed is shown in Table 4 . Anaesthetic techniques used were as follows: general anaesthesia alone 16 cases; combined general and regional technique 93 cases; regional anaesthesia alone 107 cases (spinal 70; epidural 2; combined spinal/epidural 27; type: 8 not stated). Eight patients received aprotinin (procedures undertaken before withdrawal of the drug) and 28 received tranexamic acid; 25 of these 36 cases were at a single site, which treated 25 of 44 cases with antifibrinolytic drugs.
Perioperative cell salvage data
Perioperative cell salvage was utilized in five of the 11 hospitals, all of which were in the medium to high case volume groups ( Table 2) . A description of cell salvage use and transfusion outcomes is shown in Figure 1 . In total, 88 (42%) of cases had a cell saver set up for surgery, and red cells were re-infused in 68 cases. For the 68 cases in which red cell re-infusion took place, the mean (95% CI) re-infused volume was 312 (260-362) ml per case. The distribution of re-infusion volumes is shown in Figure 2 . Unadjusted comparison between patients who did not receive salvaged red cells and patients who received red cell salvage showed that those receiving cell salvage were less likely to require allogeneic RBC transfusion during surgery (9% vs 40%) and during the combined intra-/postoperative period (55% vs 63%). Preoperative Hb concentrations for patients who received cell salvage were similar to those in whom it was not used. Cell salvage was more frequently used for combined femoral/acetabular revisions than single component or 'other' surgical procedures (Table 4) . Estimated operating theatre blood loss
The overall mean (95% CI) estimated theatre blood loss was 1013 (899 -1128) ml. The estimated blood loss was higher for combined femoral/acetabular revision and femoral revision than the other categories ( Table 4 ). The estimated blood loss was relatively low for the 20 patients in whom cell salvage was set up but no red cell re-infusion occurred (median 450 ml; 1st quartile 350 ml; 3rd quartile 644 ml), suggesting that salvage may not have been feasible for these cases.
Allogeneic RBC transfusion
Overall, 57.7% of patients received an RBC transfusion in the perioperative period (day of surgery up to 7 days after operation). In relation to surgery, 3.8% of patients received preoperative transfusions, 29.5% were transfused during surgery, and 44.7% were transfused after operation. Overall, the mean (95% CI) red cell use per case (including non-transfused patients) was 1. 
Factors associated with requiring allogeneic RBC transfusion
In the first regression model (Table 5A) , which included only preoperative factors and the type of surgery and anaesthesia, the univariate analysis showed an association between greater risk of requiring a perioperative RBC transfusion and lower preoperative Hb, lower patient weight, and female gender. In multivariable analysis, the only significant independent associations with higher risk of blood transfusion were with lower preoperative Hb and patient weight, although the surgical procedure approached significance primarily as a result of the difference between acetabular replacements alone vs combined acetabular/femoral replacement. In the second regression model, which included estimated operating theatre blood loss and cell salvage-related variables (Table 5B) , the univariate analysis found associations between higher risk of receiving RBC transfusions and lower preoperative Hb and patient weight, female gender, and higher operating theatre blood loss. In the multivariable model, independent associations were found between higher risk of blood transfusions and lower preoperative Hb and patient weight and higher operating theatre blood loss. There was also an independent association between receiving RBC re-infusion from the cell saver and a lower blood transfusion rate. There was a trend towards an association between the case being undertaken in a centre using cell salvage and a lower risk of RBC transfusion, but this did not reach statistical significance.
Discussion
In a multicentre prospective cohort study of RHA, we have shown that 58% of patients required ABTs during the perioperative period, receiving a mean (95% CI) of 1.8 red cell units (1.52 -2.08) per operated case. In multivariable analysis of predefined factors that may be associated with a greater risk of ABT, a lower preoperative Hb and patient weight had the strongest independent associations with greater transfusion risk. We collected data from a representative sample of hospitals including centres with a wide range of surgical volumes which, together with the completeness of our data, suggest a low risk of bias and high generalizability. We defined our variables of interest a priori by consensus based on an earlier national survey, 12 review of the literature, and the expert opinion of surgeons and anaesthetists undertaking RHA surgery. Although residual confounding by unmeasured variables cannot be excluded, we consider it unlikely that we failed to measure important factors that may have altered the associations we observed. Among the patients studied, 121 were transfused (58%); this number of 'events of interest' justified the inclusion of 13 variables in the multivariable analysis ( 10 'events of interest' per factor evaluated), suggesting a relatively low risk of type II error in the associations we observed. A criticism of previous randomized trials and studies of blood conservation technologies in surgery has been the heterogeneity of procedures undertaken on the included patients, which limits the validity of findings to specific surgical procedures. In addition, lack of control of other potentially important factors such as perioperative transfusion trigger and surgical technique make interpretation of the evidence difficult, especially comparing recent with older studies. These factors were noted in systematic reviews of cell salvage and the use of antifibrinolytics in orthopaedic surgery.
6 -10 13 14 We chose to study only RHA, because this procedure is associated with a high risk of ABT. Studying a single procedure minimized the confounding effect of the surgery itself on the associations found and allowed us to include different subtypes of the procedure in the analysis.
For the univariate analysis, this suggested that acetabular revision alone was associated with significantly lower blood loss than femoral or combined procedures. We collected data on the postoperative transfusion triggers used, which were relatively restrictive and consistent with recent evidence-based guidelines, 15 16 providing evidence that our findings are externally valid to other populations using evidence-based transfusion thresholds in the perioperative period.
Our data indicate that preoperative anaemia and patient weight are strong predictors of the need for ABT in revision hip surgery, which confirms the finding of previous studies in orthopaedic surgery. 2 6 An association with female gender has also been shown previously, but in our regression model, this was not significant in the multivariable model, most likely because of the interaction with patient weight which correlates with circulating blood volume. Female patients also tend to have lower preoperative Hb concentration than males. The introduction of intraoperative factors in the second regression model found a strong association between the estimated blood loss and greater ABTs, which was unsurprising. Importantly, however, re-infusion of salvaged RBCs remained as a significant predictor of lower ABT risk, suggesting that the successful use of cell salvage was clinically useful and important. The costeffectiveness of technologies such as PCS will vary according to a range of factors including individual patient characteristics, the surgery performed, and the baseline rates of ABT. The additional patient benefit of transfusion avoidance is also relevant. An association between ABT and increased perioperative complications has been found in previous studies of orthopaedic surgery, although proving causation is difficult in cohort studies. 6 The gold standard for assessing the clinical-and cost-effectiveness of cell salvage for RHA would be a randomized trial, but the high uptake of cell salvage in routine practice means that clinical equipoise is often lacking among surgeons and anaesthetists, especially those already using the technology. Although our cohort study provides a lower evidence quality than a randomized trial, it provides strong supportive evidence for a clinically important ABT-sparing effect in RHA as a component of the current blood conservation strategies. Our data justify the routine use of intraoperative cell salvage for patients with preoperative anaemia and low body weight, and strongly support the use for all patients having combined femoral/acetabular procedures or other procedures for which the surgeon anticipates a high blood loss. The mean re-infusion volume of 312 ml, equivalent to 1 allogeneic RBC unit, suggests likely cost-effectiveness measured against the cost of disposables alone even if the other clinical benefits of ABT avoidance and the reduced demands on blood services are not taken into account. However, our observation that 25% of cases in which cell salvage was set up did not have autologous blood re-infused emphasizes the importance of appropriate case selection. Our findings are consistent with a retrospective case-matched study, which found a large reduction in ABT rate for patients managed with PCS (on average 4 red cell units per case). 17 The smaller effect seen in our cohort was probably a reflection of the lower overall transfusion rates, which may be explained by improved surgical techniques and more restrictive transfusion triggers. The use of antifibrinolytics was low in our cohort, and most use occurred in a single centre, which made assessment of their association with allogeneic RBC transfusion difficult to assess. Previous systematic reviews have suggested that antifibrinolytic agents reduce blood loss and possibly RBC requirements in orthopaedic surgery, but most studies are potentially confounded by the same factors noted above for evaluations of cell salvage. 7 11 14 In addition, interaction between antifibrinolytics and cell salvage has not been evaluated or the safety profile, especially for thrombotic events, conclusively established. 14 In conclusion, for RHA, we have confirmed the association between preoperative anaemia and patient weight and the risk of perioperative ABTs. After adjusting for other potentially important confounding factors, we have demonstrated that intraoperative cell salvage decreases the chance of requiring ABT during the perioperative period and typically results in re-infusion of about 1 unit of autologous red cells.
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